A proof-of-concept study to assess the effect of ACT-451840 against early Plasmodium falciparum blood stage infection in healthy subjects
Latest Information Update: 16 Jul 2019
At a glance
- Drugs ACT 451840 (Primary)
- Indications Falciparum malaria
- Focus Proof of concept; Therapeutic Use
- Sponsors Actelion Pharmaceuticals
- 01 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 28 Jul 2014 New trial record